Hikma Pharmaceutical Narrows FY2026 Group Operating Profit Range To $740 Million-$760 Million

By Reuters News

- Hikma Pharmaceuticals PLC HIK.L:

  • HIKMA PHARMACEUTICAL - TRADING STATEMENT

  • HIKMA - NARROWS FY2026 GROUP OPERATING PROFIT RANGE TO $740 MILLION-$760 MILLION

  • HIKMA - REITERATES FY2026 GROUP REVENUE GROWTH OUTLOOK OF 2%-4%

  • HIKMA - CONFIRMS BECKY HALL TO JOIN AS CFO ON MARCH 8, 2027

Further company coverage: HIK.L

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk